Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma.
Mael LeverSimon BognerMelina GiousmasFabian D MairingerHideo A BabaHeike RichlyTanja GromkeMartin SchulerNikolaos E BechrakisHalime KalkavanPublished in: Pigment cell & melanoma research (2024)
Approximately every second patient with uveal melanoma develops distant metastases, with the liver as the predominant target organ. While the median survival after diagnosis of distant metastases is limited to a year, yet-to-be-defined subgroups of patients experience a more favorable outcome. Therefore, prognostic biomarkers could help identify distinct risk groups to guide patient counseling, therapeutic decision-making, and stratification of study populations. To this end, we retrospectively analyzed a cohort of 101 patients with newly diagnosed hepatic metastases from uveal melanoma by using Cox-Lasso regression machine learning, adapted to a high-dimensional input parameter space. We show that substantial binary risk stratification can be performed, based on (i) clinical and laboratory parameters, (ii) measures of quantitative overall hepatic tumor burden, and (iii) radiomic parameters. Yet, combining two or all three domains failed to improve prognostic separation of patients. Additionally, we identified highly relevant clinical parameters (including lactate dehydrogenase, thrombocyte counts, aspartate transaminase, and the metastasis-free interval) at first diagnosis of metastatic disease as predictors for time-to-treatment failure and overall survival. Taken together, the risk stratification models, built by our machine-learning algorithm, identified a comparable and independent prognostic value of clinical, radiological, and radiomic parameters in uveal melanoma patients with hepatic metastases.
Keyphrases
- newly diagnosed
- machine learning
- end stage renal disease
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- high resolution
- skin cancer
- mass spectrometry
- peripheral blood
- artificial intelligence
- patient reported outcomes
- breast cancer risk